Should Sangamo's Failure Make CRISPR Investors Nervous? [The Motley Fool]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: The Motley Fool
Should Sangamo's Failure Make CRISPR Investors Nervous? The first look at a revolutionary new gene therapy from Sangamo Therapeutics ( NASDAQ:SGMO Editas Medicine NASDAQ:EDIT Crispr Therapeutics NASDAQ:CRSP Did the market overreact to an unrelated problem, or does Sangamo's flop truly suggest trouble ahead for CRISPR stocks? As you may have guessed, the answer isn't that simple. Image source: Getty Images. Reasons to relax Sangamo Therapeutics, Editas Medicine, and Crispr Therapeutics are all trying to help patients produce proteins that they can't make on their own, but Sangamo's the only one using zinc-finger nucleases to get the job done. Investors holding CRISPR stocks should know that this gene-editing tool has been around a long time, without much to show for it. Sangamo's been working with zinc finger nucleases for decades Patients with Hunter syndrome lack a digestive enzyme called iduronate--sulfatase (IDS), and SB-9 aims to fix the problem by delivering a working copy of the
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsBusiness Wire
- Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingBusiness Wire
SGMO
Earnings
- 5/9/24 - Miss
SGMO
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/30/24 - Form 8-K
- SGMO's page on the SEC website